...
首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer.
【24h】

The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer.

机译:神经内分泌标记和预测价值p53响应对化疗和生存晚期非小细胞肺癌患者癌症。

获取原文
获取原文并翻译 | 示例
           

摘要

Background: A minority of patients (30-40%) with advanced non-small cell lung cancer (NSCLC) have objective responses to chemotherapy. Therefore, defining molecular features that determine resistance or response to chemotherapy would have important implications in this disease. Several studies have suggested that patients whose tumors have neuroendocrine features may be more responsive to chemotherapy. In addition, increased expression of p53 may play a role in chemotherapy resistance in patients with NSCLC. Methods: The objective of this study was to analyze retrospectively, the correlation between marker expression and response to chemotherapy and survival using immunohistochemistry for neuroendocrine markers and p53. Ninety patients with unresectable stage III or IV NSCLC, treated with platinum based combination chemotherapy were evaluated. The pathological specimens were obtained prior to chemotherapy. Results: There was no statistically significant correlation between any individual marker and response to chemotherapy. However, patients with tumors with increased expression of p53 were more likely to have progressive disease following chemotherapy (P=0.02). Similarly, patients with tumors lacking neuroendocrine expression and with increased expression of p53 were more likely to have progressive disease when compared to patients with tumors with normal p53 expression and neuroendocrine differentiation (P=0.03). Normal expression of p53 along with the presence of neuroendocrine differentiation was a favorable factor for both survival (P=0.05) and time to disease progression (P=0.04) in the multivariate analysis. Conclusion: The presence of neuroendocrine markers alone was not predictive of response to chemotherapy and did not impact on the survival of this group of patients with advanced stage NSCLC. The normal expression of p53 together with neuroendocrine differentiation seems to impact favorably on overall survival time and time to disease progression without significant improvement in response to chemotherapy.
机译:背景:少数患者(30 - 40%)先进的非小细胞肺癌(NSCLC)目的对化疗的反应。定义分子特性决定化疗会抵抗或响应这种疾病的重要意义。研究表明,病人的肿瘤神经内分泌功能可能更吗对化疗。p53的表达增加可能发挥的作用在非小细胞肺癌患者化疗抵抗。方法:本研究的目的是回顾历史,分析之间的关系标记表达式和对化疗的反应用免疫组织化学和生存神经内分泌标志物和p53。不可切除的阶段III或IV NSCLC的治疗基于铂的联合化疗评估。在化疗之前获得。没有统计上显著的相关性任何个人标记和响应之间的关系化疗。p53的表达更有可能增加有进步的疾病化疗后吗(P = 0.02)。神经内分泌表达式和增加p53的表达更有可能进步的疾病患者相比与正常p53表达与肿瘤神经内分泌分化(P = 0.03)。随着的存在p53的表达神经内分泌分化是有利的因素对生存(P = 0.05)和时间疾病进展在多元(P = 0.04)分析。神经内分泌标志物就没有预测对化疗的反应,不影响这组患者的生存晚期非小细胞肺癌。p53与神经内分泌分化似乎影响总体存活率疾病进展时间和时间在应对显著改善化疗。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号